TOKYO, May 20 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported significant warrant exercises during the period from May 1 to May 19, 2026.
A total of 2,604 warrants were exercised, representing approximately 1.63% of the total outstanding warrants issued to EVO FUND on August 1, 2025. As of April 30, 2026, there were 160,000 unexercised warrants remaining out of the initial issuance.
On May 1, 2026, 511 warrants were exercised, followed by daily exercises ranging from 465 to 473 warrants until May 19, 2026. The company's total outstanding shares stood at 8,078,200 as of April 30, 2026, including 183 treasury shares.
Detailed information on the warrant issuance can be found in the July 16, 2025, press release titled “Third-party Allocation Issuance of the Sixteenth Tranche Warrants (with Exercise Price Adjustment Clause) and Conclusion of Subscription Right Purchase Contract.”.
🟡 Confidence: Standard AI-translated content.